BCL-2

Assets acting on this target.

Class
Small molecule BCL-2 inhibitor
Pathway
Intrinsic (mitochondrial) apoptosis pathway

BCL-2 is a protein that helps cells survive by blocking apoptosis, the programmed cell death process that normally eliminates damaged or unneeded cells. It works within the intrinsic, or mitochondrial, apoptosis pathway, where a family of related proteins constantly balance pro-survival and pro-death signals at the mitochondrial membrane. Many cancer cells, particularly certain blood cancers, produce excess BCL-2, allowing malignant cells that should die to persist and accumulate. Small molecule BCL-2 inhibitors are designed to occupy the groove on BCL-2 that normally sequesters pro-apoptotic partner proteins, releasing them so they can trigger mitochondrial outer membrane permeabilization and commit the cell to death. Because this approach exploits a survival dependency that many tumor cells have come to rely on, it can selectively induce apoptosis in malignant populations while sparing normal cells that are less reliant on BCL-2 for survival. This mechanism is broadly relevant across hematologic malignancies such as leukemias and lymphomas, where BCL-2 overexpression is common, and is being explored in various combination strategies. The approach represents a rational, structure-based way of directly re-enabling a cell's own death machinery rather than relying on external immune or genotoxic mechanisms.

By indication

Related mechanisms

BCL-2 drugs compared

10 drugs, stage by indication
10 drugs acting on BCL-2: developer, modality, furthest stage and stage in each indication. Furthest stage first.
DrugDeveloperModalityFurthest stageStage by indication
SonrotoclaxBeqalziBeOne Medicinessmall moleculeApprovedApproved in Mantle Cell Lymphoma; Phase 3 in Chronic Lymphocytic Leukemia; Phase 2 in Acute Myeloid Leukemia
VenetoclaxAbbVie, Rochesmall moleculeApprovedApproved in Acute Myeloid Leukemia; Approved in Chronic Lymphocytic Leukemia; Phase 3 in Multiple Myeloma
LisaftoclaxAscentage Pharma Group Inc.small moleculePhase 3Phase 3 in Acute Myeloid Leukemia; Phase 3 in Relapsed/Refractory Chronic Lymphocytic Leukemia; Phase 1/2 in Multiple Myeloma; Phase 1/2 in Systemic Lupus Erythematosus
MesutoclaxBeijing InnoCare Pharma Tech Co.small moleculePhase 3Phase 3 in Acute Myeloid Leukemia; Phase 3 in Mantle Cell Lymphoma; Phase 2/3 in Chronic Lymphocytic Leukemia
FCN-338Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.small moleculePhase 2Not recorded
SurzetoclaxAbbViesmall moleculePhase 1/2Phase 1/2 in Multiple Myeloma
TGRX-814Shenzhen TargetRxsmall moleculePhase 1/2Phase 1/2 in Acute Myeloid Leukemia
BGB-21447BeOne Medicinessmall moleculePhase 1Phase 1 in HR+/HER2- Metastatic Breast Cancer
FXS0683Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.small moleculePhase 1Phase 1 in Acute Myeloid Leukemia
LonitoclaxLomond Therapeutics Holdings, Inc.small moleculePhase 1Phase 1 in Acute Myeloid Leukemia

← all mechanisms